Citations (11)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Handrean Soran & Paul Durrington. (2008) Rosuvastatin: efficacy, safety and clinical effectiveness. Expert Opinion on Pharmacotherapy 9:12, pages 2145-2160.
Read now
Read now
John R Crouse$suffix/text()$suffix/text(). (2008) An evaluation of rosuvastatin: pharmacokinetics, clinical efficacy and tolerability. Expert Opinion on Drug Metabolism & Toxicology 4:3, pages 287-304.
Read now
Read now
Herbert Schuster. (2007) The GALAXY Program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk. Expert Review of Cardiovascular Therapy 5:2, pages 177-193.
Read now
Read now
Jun-ren Zhu, Brian Tomlinson, Young Moo Ro, Kui-Hian Sim, Yuan-Teh Lee & Charn Sriratanasathavorn. (2007) A randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY-Asia study). Current Medical Research and Opinion 23:12, pages 3055-3068.
Read now
Read now
Articles from other publishers (7)
Miao Hu, Sandra S.H. Lui, Gary T.C. Ko & Brian Tomlinson. (2013) Do the lipid responses to rosuvastatin and atorvastatin differ between Chinese and Caucasians? Comparison of the DISCOVERY-Hong Kong study with other DISCOVERY studies. International Journal of Cardiology 168:3, pages 3071-3073.
Crossref
Crossref
Henrique A. R. Fonseca, Maria C. Izar, Henrique T. Bianco & Francisco A. Fonseca. (2010) Ezetimibe, Oxidized Low Density Lipoprotein, Lp (a), and Dyslipidemia. Journal of Atherosclerosis and Thrombosis 17:8, pages 888-888.
Crossref
Crossref
John Wlodarczyk, David Sullivan & Michael Smith. (2008) Comparison of Benefits and Risks of Rosuvastatin Versus Atorvastatin from a Meta-Analysis of Head-to-Head Randomized Controlled Trials. The American Journal of Cardiology 102:12, pages 1654-1662.
Crossref
Crossref
Abdelkarim Waness, Sami Bahlas & Saad Al Shohaib. (2008) Simvastatin-Induced Rhabdomyolysis and Acute Renal Injury. Blood Purification 26:4, pages 394-398.
Crossref
Crossref
Susan J. Appel, Natalie A. Floyd & Emily J. Jones. (2007) Reducing Cardiovascular Risk and Managing Dyslipidemia in Women. Nursing for Women's Health 11:6, pages 586-599.
Crossref
Crossref
Evan A. Stein, A. David Marais, Jean Ducobu, Michel Farnier, Dov Gavish, Hans Hauner, Andrew J. Kaplan, Florence Le Maulf & Helena Melezínková. (2007) Comparison of short-term renal effects and efficacy of rosuvastatin 40 mg and simvastatin 80 mg, followed by assessment of long-term renal effects of rosuvastatin 40 mg, in patients with dyslipidemia. Journal of Clinical Lipidology 1:4, pages 287-299.
Crossref
Crossref
Kheng-Thye Ho, Khong-Whee Chin, Kheng-Siang Ng, Evo Alemao, Srinivasan Rajagopalan & Don Yin. (2006) The A-SACT (Achievement in Singapore of Cholesterol Targets) Study in Patients with Coronary Heart Disease. American Journal of Cardiovascular Drugs 6:6, pages 383-391.
Crossref
Crossref